Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $13.39.

A number of equities research analysts have recently commented on VYGR shares. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group cut their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th.

Voyager Therapeutics Stock Performance

Shares of VYGR opened at $3.28 on Friday. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The firm's 50-day simple moving average is $3.45 and its two-hundred day simple moving average is $4.84. The stock has a market cap of $181.50 million, a PE ratio of 4.62 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. Equities research analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 6.39% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Armistice Capital LLC raised its stake in Voyager Therapeutics by 0.7% during the 1st quarter. Armistice Capital LLC now owns 5,436,000 shares of the company's stock valued at $18,374,000 after buying an additional 40,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Voyager Therapeutics by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company's stock worth $18,232,000 after acquiring an additional 29,014 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock worth $14,576,000 after acquiring an additional 278,700 shares during the period. Dimensional Fund Advisors LP increased its position in Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after acquiring an additional 275,571 shares during the last quarter. Finally, Vestal Point Capital LP lifted its holdings in Voyager Therapeutics by 1.6% in the first quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company's stock valued at $4,223,000 after acquiring an additional 19,418 shares during the period. Institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.